openFDA
Cure8 regulatory brief
METHYLPREDNISOLONE SODIUM SUCCINATE FDA label update (2026-07-24)
Medications
Prednisone
Corticosteroids
Steroids
Regulatory Update
Clinicians
Patients On Biologics
Ulcerative colitis
Why This Matters
This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and safety warnings that matter when steroids are given intravenously or intramuscularly.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis who may require short-term systemic corticosteroids, clinicians who administer IV/IM steroids, and caregivers involved in acute IBD care.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA drug-label record (DailyMed) describing the approved uses, dosing, and safety information for methylprednisolone sodium succinate for injection. It includes guidance for emergency high-dose IV use, recommended infusion practices, and cautions about mixing or diluting the product.
The label specifically lists “regional enteritis (systemic therapy)” and “ulcerative colitis” as gastrointestinal indications where injectable methylprednisolone may be used to tide a patient over a critical period.
If you or your clinician are considering corticosteroid injections for an IBD flare, this label underscores that the product is intended for short-term use in acute/critical situations and that dosing must be individualized; it also highlights specific preparation and administration precautions (reconstitution, compatible diluents) and rare but serious cardiac risks with very rapid large IV doses.
If you need practical decisions (whether to use injectable methylprednisolone, exact dosing, or monitoring), discuss the details with your prescribing clinician because the label is a technical regulatory document and not a substitute for individualized medical advice.
Keep In Mind
This is a regulatory drug-label record (DailyMed) summarizing approved indications and safe-use instructions. It is not treatment guidance tailored to individual patients. The label emphasizes short-term use for acute episodes and includes administration and safety precautions; clinicians should interpret dosing and risks in the context of each patient’s overall care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorHF Acquisition Co LLC, DBA HealthFirst
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 24, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SOLU-MEDROL FDA label update (2026-07-23)
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Prednisone FDA label update (2026-07-13)
The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...
Dexamethasone FDA label update (2026-07-07)
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...